Figure 5.

(A) Viability of A549 cells treated with aptamers and palivizumab. Cells were incubated with 10 nM of aptamers or palivizumab for 48 h, then their viability was assessed. Neither Palivizumab, nor any of the aptamers had a significant detrimental effect on the cell viability after 48 h. (B) Dose-dependent effect of one of the most promising modified aptamer candidates and a non-relevant aptamer on the viability of A549 cells. Cells were incubated with 50, 25 and 10 nM of modified aptamer or non-relevant aptamer for 48 h, then their viability was assessed. Neither the modified aptamer, nor the non-relevant aptamer had a detrimental effect on the cell viability after 48 h. Error bars indicate the standard deviation of three individual experiments (N = 3).